5 best EDC platforms for basket and umbrella trials 2026

A protocol amendment in a basket or umbrella trial isn't a routine edit. Adding a cohort, dropping an arm, or updating eligibility criteria touches the entire study architecture, and if your electronic data capture (EDC) system can't absorb that change without downtime, your data management team ends up managing the platform instead of the trial. This comparison evaluates five EDC platforms for sponsors and CROs running basket and umbrella designs, weighing mid-study amendment velocity, multi-cohort architecture, randomization integration, and compliance continuity across evolving protocol versions. Viedoc's EDC software is built for exactly this kind of protocol churn, with studies averaging 10 weeks from signed work order to go-live even at this level of complexity, backed by a no-code Designer your team can amend independently.

You're not choosing a platform for a single, static protocol. You're choosing one that has to absorb interim analyses, new sub-studies, and biomarker-driven eligibility changes without forcing a rebuild every time the statistical plan shifts. Reconciliation gaps between EDC and randomization and trial supply management (RTSM) systems compound fast when arms open and close mid-trial, and QA teams need an audit trail that stays coherent across every version of the protocol, not just the one currently active.

Generic or oversized enterprise platforms tend to fail this segment in one of two directions: either they require vendor programmers for every arm addition, which turns a two-week amendment into a two-month one, or they're built for single-arm, single-cohort simplicity and buckle once you're managing five sub-studies with independent randomization schemes. The platforms below were selected for how they handle that middle ground.

Best EDC solutions for basket and umbrella trials: quick comparison

These five eClinical platforms represent the most evaluated options for basket and umbrella trial sponsors and CROs, reviewed across amendment velocity, multi-cohort architecture, and compliance continuity.

1. Viedoc

Viedoc's EDC software is built around the reality that basket and umbrella protocols change shape mid-study. Studies powered by Viedoc average 10 weeks from signed work order to go-live, and the platform is designed to handle multiple endpoints, hybrid sites, and adaptive arms without slowing operations. In a verified case study, biotech Citryll and CRO Clinfidence used Viedoc for a four-stage adaptive Phase 1 trial where results from each stage informed the next, absorbing 17 mid-study protocol amendments without disrupting data collection.

For cohort-level design work, Viedoc Designer lets your data management team configure new arms and eligibility logic in-house, without waiting on a vendor programmer. When a study also needs adaptive or dynamic allocation across cohorts, Viedoc's Randomization software integrates directly with the EDC to keep enrollment and arm assignment reconciled as the protocol evolves.

Every study stays inspection-ready through the Viedoc Inspection Readiness Packet (VIRP), with compliance spanning 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA, backed by ISO 27001 and SOC 2 certification and 24/7 customer success.

"It offers customisable study workflow and tailoring it according to trial specification is easy," said Sanchita V., a Data Manager, on G2.

• Study scale: 8,000+ studies run on Viedoc across 75+ countries
• Build speed: Study builds average 10 weeks for professional-services-managed protocols of this complexity
• Compliance: 21 CFR Part 11, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Adaptive design support: Multiple endpoints, hybrid sites, and adaptive arms without slowing operations
• Inspection readiness: VIRP available to all customers
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Rave EDC, an enterprise electronic data capture system that the vendor positions explicitly for basket, umbrella, and platform trial protocols. The platform is built to implement mid-study changes, whether preplanned adaptive elements or unplanned protocol amendments, without requiring system downtime. Medidata reports that it and its customers perform an average of more than 30,000 mid-study changes per year, and more than 300,000 since 2005, across studies that include large-scale, long-running trials.

Rave EDC integrates with Rave RTSM to drive randomization, dispensation, and supply inventory management directly from the EDC interface, reducing duplicate data entry between systems as arms open and close. The platform also supports granular, auditable configuration and testing of study design changes before they go live, alongside applications for imaging and clinical trial management. Rave EDC is used across Phase I through Phase IV studies, including large-scale oncology and rare disease programs with complex, evolving protocols.

3. Veeva

Veeva offers Veeva EDC as part of the Vault Clinical Suite, a cloud platform built to run master protocols and adaptive designs without downtime for mid-study changes. Its Event Groups feature lets study designers group visits into individual treatment arms, cohorts, or entire sub-studies within a single environment, while Subject Groups support named groupings of study participants for tracking and reporting across a multi-cohort design.

The platform's Difference Report compares casebook versions after an amendment, isolating exactly what changed so user acceptance testing can focus on the affected items rather than retesting the entire database. Veeva EDC is used by several of the world's largest biopharma companies and is built on an in-product specification studio that reduces reliance on custom programming for complex study builds. It is available as a standalone product or as part of the broader Vault Clinical Data Management suite alongside eTMF, CTMS, and study startup applications.

4. Castor

Castor offers Castor EDC, a no-code electronic data capture and eCOA platform that the vendor markets specifically for adaptive, basket, and umbrella oncology trial designs. According to Castor, its architecture supports mid-study amendments, including adding cohorts or modifying dosing arms, without downtime or a full system rebuild. The platform's patient-facing app supports bring-your-own-device electronic patient-reported outcomes, which Castor cites as achieving over 95% compliance for quality-of-life endpoints in oncology studies.

Castor's platform has been deployed at global scale, including a World Health Organization trial spanning 5,000 investigators across 600 sites in 52 countries with adaptive medication allocation built in. The platform supports FDA 21 CFR Part 11, GDPR, and HIPAA compliance, with a full audit trail recording user, timestamp, and change for every data point. Castor also offers consultancy services for translating complex protocols into study databases.

5. Medrio

Medrio offers Medrio CDMS/EDC, a unified clinical data management platform that combines electronic data capture with integrated ePRO/eCOA, eConsent, and RTSM in a single environment. The platform uses point-and-click configuration rather than custom coding, which the vendor positions as enabling flexible mid-study changes without a programmer. Medrio's eCOA/ePRO module is built to support adaptive and complex study designs where outcome assessments may change over time, integrated directly with the core EDC/CDMS database.

Medrio CDMS/EDC includes validated electronic records and signatures, full audit trails, and role-based access controls, aligning with FDA 21 CFR Part 11, ICH E6(R2), HIPAA, and GDPR. The platform is positioned by the vendor toward small-to-mid-size sponsors and CROs, with particular strength in early-phase and MedTech study designs.

What to look for in EDC solutions for basket and umbrella trials

Mid-study amendment velocity without downtime

In a basket or umbrella design, a protocol amendment isn't an edge case. It's the operating model. The evaluation question isn't whether a platform supports amendments, but whether adding a cohort or closing an arm takes the live database offline while it happens.

Best-in-class platforms let you build and test a change in a development environment, then push it live without interrupting data collection on the arms that are unaffected. Look for evidence of amendment volume at scale, not just a feature claim.

Overlooking this criterion means every biomarker-driven eligibility update or interim-analysis-triggered design change becomes a scheduling dependency on your EDC vendor, which compounds across every sub-study in the trial.

Multi-cohort and sub-study architecture

A platform built for single-arm trials treats a new cohort as a new database. A platform built for basket and umbrella designs treats it as a configuration change within the same study architecture, with shared infrastructure across sub-studies and independent reporting per cohort.

Best-in-class platforms let you group visits, forms, and randomization logic by treatment arm or sub-study while keeping a single source of truth for cross-cohort reporting and safety monitoring. This distinction matters most once you're running more than two or three concurrent sub-studies under one master protocol.

Randomization and RTSM integration

Basket and umbrella trials frequently combine static and dynamic randomization across cohorts, and reconciliation gaps between EDC and RTSM are one of the most common sources of data quality issues in adaptive designs. Evaluate whether randomization is natively integrated with the EDC or bolted on through a separate vendor relationship.

Best-in-class integration means enrollment, arm assignment, and dispensation data flow through a single interface without manual reconciliation, even as arms are added or closed mid-study.

Compliance and audit trail continuity across protocol versions

Every amendment creates a new protocol version, and QA teams need an audit trail that stays coherent across all of them, not just the currently active one. This is a harder requirement than standard 21 CFR Part 11 compliance, since inspectors will expect to trace a data point back through every version of the eCRF it passed through.

Platforms that handle this well maintain version-linked audit trails and validation documentation automatically, without requiring your QA team to reconstruct the amendment history manually at inspection time.

How to choose the right EDC solution for basket and umbrella trials

Step 1: Define your cohort and sub-study count at steady state

Don't evaluate against your trial's cohort count at launch. Define what steady-state complexity looks like once interim analyses have run and new sub-studies have been added, since that's the load your EDC actually needs to carry.

Step 2: Assess your realistic amendment cadence

Estimate how often you expect protocol amendments based on your trial's design, not a generic industry average. A biomarker-driven umbrella trial with quarterly interim analyses has a fundamentally different amendment cadence than a two-arm basket trial with a fixed enrollment window.

Step 3: Scrutinize RTSM integration depth, not just presence

Many platforms claim RTSM integration. Fewer handle reconciliation cleanly when arms open and close mid-study. Ask vendors for a specific walkthrough of what happens to randomization data when a cohort is added six months into an active trial.

Step 4: Evaluate whether your team can execute amendments in-house

A platform that requires vendor programmers for every arm addition turns your amendment cadence into a scheduling dependency. Assess whether your data management team can configure a new cohort themselves, and how long that realistically takes.

Step 5: Match platform complexity to your trial's actual phase and scale

If you're running an early-to-mid-phase basket or umbrella design with a handful of cohorts, Viedoc's EDC software gives you low-code configuration and integrated randomization without the overhead of an enterprise platform built for hundreds of arms. Book a demo to walk through your specific cohort structure and amendment cadence.

Frequently asked questions

What is the best EDC software for basket and umbrella clinical trials?

Viedoc's EDC software is a strong fit for early-to-mid-phase basket and umbrella trials, with a low-code Designer that supports multiple endpoints, hybrid sites, and adaptive arms, and study builds averaging 10 weeks even at this level of protocol complexity. Medidata is the category benchmark for large-scale, enterprise basket and umbrella platform trials, with deep RTSM integration and a track record of high-volume mid-study changes. Castor is also a strong alternative, marketing its no-code architecture specifically for adaptive oncology designs.

What should I look for when choosing an EDC platform for adaptive trial designs?

Prioritize mid-study amendment velocity without database downtime, native multi-cohort or sub-study architecture, and tight integration between the EDC and your randomization system. Compliance and audit trail continuity across protocol versions matters as much as any feature list, since inspectors will trace data through every amendment your trial has undergone.

How long does it take to build and deploy a basket or umbrella trial on a modern EDC platform?

Timelines vary by protocol complexity and vendor model. Professional-services-managed builds for protocol-heavy adaptive designs average around 10 weeks from signed work order to go-live, though simpler amendments to an existing study database typically take days rather than weeks once the initial architecture is in place.

How does EDC amendment handling differ for basket versus umbrella trial designs?

Basket trials typically add or modify cohorts within a single biomarker-defined population, while umbrella trials manage multiple sub-studies under one master protocol, often with different treatment arms per biomarker subgroup. Both require an EDC that can implement structural changes without taking the live database offline, though umbrella trials place heavier demands on cross-sub-study reporting and independent randomization schemes per arm.

What compliance certifications matter most for adaptive oncology trials?

21 CFR Part 11 electronic signature compliance, GDPR and EU Annex 11 for data protection, and ICH GCP are baseline requirements. For platforms hosting global multi-cohort trials, ISO 27001 and SOC 2 certification confirm the underlying infrastructure meets recognized security standards, which QA teams will verify during vendor selection regardless of trial phase.

Can a mid-market EDC platform handle a large-scale umbrella trial with dozens of sub-studies?

It depends on scale and vendor model. Mid-market platforms with low-code configuration handle a handful of concurrent sub-studies well, particularly in Phase I/II settings. For umbrella trials spanning dozens of biomarker-driven sub-studies at enterprise scale, platforms with deep, purpose-built RTSM integration and extensive amendment volume history, such as Medidata or Veeva, are generally better matched to that level of complexity.

Making the right EDC choice for basket and umbrella trials

The EDC platforms reviewed here share a common recognition that basket and umbrella designs demand mid-study flexibility as a core capability, not an add-on, though they arrive at it through different architectures, from enterprise-grade platforms built for high-volume amendment activity to no-code systems designed for smaller data management teams. The global eClinical software market is estimated at over $11 billion in 2025, growing at approximately 14% annually, a pace driven in large part by exactly this shift toward adaptive and master protocol designs.

Matching platform to requirement comes down to a few core variables: your steady-state cohort count, your realistic amendment cadence, how deeply randomization needs to integrate with your EDC, and whether your team can execute changes in-house or needs vendor programming support. US-based teams tend to weight speed and in-house configuration ability more heavily; EMEA and APAC teams often weight compliance credentials and long-term vendor stability higher given regional audit expectations.

Switching EDC vendors mid-trial is costly and disruptive, particularly once a validated database has real subject data in it. That makes the platform decision for an adaptive design one worth getting right at the outset, before the first protocol amendment forces the question.

Why Viedoc is the best fit for growing basket and umbrella trial programs

If you're running an early-to-mid-phase basket or umbrella trial and need your data management team to configure cohort changes without waiting on a vendor programmer, Viedoc's EDC software is built for that operating model. Studies average 10 weeks from signed work order to go-live even at this level of protocol complexity, and the platform is designed to handle multiple endpoints, hybrid sites, and adaptive arms without slowing your team down.

Operationally, that means a low-code Designer your team owns directly, unlimited user seats, transparent study-based pricing, and randomization that integrates natively rather than through a bolted-on third-party connector. Support runs 24/7 across global offices, backed by certified Designer training so your team isn't dependent on us for every configuration change.

Compliance runs deep: ISO 27001 and SOC 2 certified, 21 CFR Part 11, EU Annex 11, GDPR, and HIPAA compliant, with the Viedoc Inspection Readiness Packet keeping your audit trail coherent across every protocol version. Founded in 2003 and running across 8,000-plus studies today, we've built the platform around exactly the kind of mid-study complexity your program is navigating.

Book a demo or request a proposal and we'll walk through your specific cohort structure, amendment cadence, and compliance requirements.